Maxim Dives 61 Pct on Drug Trial Result  PHILADELPHIA (Reuters) - Maxim Pharmaceuticals Inc.  &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=MAXM.O target=/stocks/quickinfo/fullquote"&gt;MAXM.O&lt;/A&gt; said a trial to confirm the benefit of its Ceplene  drug failed to show an improvement in survival rates for  patients with liver cancer, sending its shares plunging on  Monday.